BioElectronics Announces Back Pain Clinical Study with Leading Australian Pain Center
March 08, 2019 10:36 ET
|
BioElectronics Corporation
Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back Pain FREDERICK, MD, March 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC...
etectRx's Innovative ID-Cap System Selected to Track Medication Ingestion in HIV Prevention Study
March 04, 2019 10:59 ET
|
etectRx
GAINESVILLE, Fla., March 04, 2019 (GLOBE NEWSWIRE) -- etectRx™, a privately held digital health company, is pleased to announce that its ID-Cap™ System, featuring state-of-the-art ingestion event...
Biomerica Announces Updates for H. Pylori Clinical Studies
February 05, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. ...
Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test
November 27, 2018 08:00 ET
|
Sera Prognostics, Inc.
TREETOP Study will Explore Enhancements to Sera’s Validated PreTRM® Test SALT LAKE CITY, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company, announced today that...
Lexington Provides Q3 Corporate Review
October 23, 2018 18:37 ET
|
Lexington Biosciences, Inc.
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is...
MSI Methylation Sciences, Inc. (MSI) provides an update on its corporate activities, including its recent arbitration award of $20 million USD against Quark Venture Inc (Quark)
October 18, 2018 07:06 ET
|
MSI Methylation Sciences
BURNABY, B.C., Oct. 18, 2018 (GLOBE NEWSWIRE) -- In a January 2016 press release, MSI announced the results of its first Phase 2 clinical trial designed to evaluate the efficacy and safety of...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
October 02, 2018 08:00 ET
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
September 25, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
Publication of eQUEST Study Results Demonstrate that eSight 3 is a Clinically Effective Device for the Visually Impaired
September 04, 2018 12:56 ET
|
eSight
TORONTO and LOS ANGELES, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dr. Brian Mech, President and CEO of eSight, is proud to announce the publication of results from eQUEST (The eSight Quality of Life and...